Product Description
TMS-008 is a small molecule compound belonging to the SMTP (stachybotrys microspora triprenyl phenol) compound family derived from black mold, as TMS-007/JX10, expected to have potential as a therapeutic agent for acute kidney injury (AKI) with its anti-inflammatory activity based on soluble epoxide hydrolase (sEH) inhibition as well as antioxidant activity. AKI is an indication in which renal function rapidly declines over a period of hours to days, and no drug has been approved for treatment of AKI to date. AKI can be caused by a variety of reasons, including cardiac surgery and drug side effects. In a study of patients who underwent coronary artery bypass surgery or heart valve surgery, 43% of patients developed acute kidney injury after surgery, and the mortality rate within 30 days was reported to be as high as 20%. 1 Due to these, it is expected there is a significant unmet medical need for effective therapeutic agents for AKI. (Sourced from: https://www.tms-japan.co.jp/en/ir/news/auto_20240228544256/pdfFile.pdf)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TMS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acute Kidney Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2031240084 | P1 |
Not yet recruiting |
Acute Kidney Injury |
2025-02-28 |